X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs PFIZER - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA PFIZER SUN PHARMA/
PFIZER
 
P/E (TTM) x 28.4 34.5 82.3% View Chart
P/BV x 3.0 5.4 54.9% View Chart
Dividend Yield % 0.4 0.6 67.5%  

Financials

 SUN PHARMA   PFIZER
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
PFIZER
Mar-18
SUN PHARMA/
PFIZER
5-Yr Chart
Click to enlarge
High Rs7012,365 29.6%   
Low Rs4331,625 26.7%   
Sales per share (Unadj.) Rs110.4430.3 25.7%  
Earnings per share (Unadj.) Rs11.078.7 13.9%  
Cash flow per share (Unadj.) Rs17.293.2 18.5%  
Dividends per share (Unadj.) Rs2.0020.00 10.0%  
Dividend yield (eoy) %0.41.0 35.2%  
Book value per share (Unadj.) Rs158.8586.5 27.1%  
Shares outstanding (eoy) m2,399.2645.75 5,244.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.14.6 110.7%   
Avg P/E ratio x51.625.3 203.7%  
P/CF ratio (eoy) x32.921.4 153.7%  
Price / Book Value ratio x3.63.4 104.9%  
Dividend payout %18.225.4 71.7%   
Avg Mkt Cap Rs m1,360,02191,271 1,490.1%   
No. of employees `00017.82.6 676.4%   
Total wages/salary Rs m53,6713,143 1,707.7%   
Avg. sales/employee Rs Th14,890.97,484.8 198.9%   
Avg. wages/employee Rs Th3,017.11,195.0 252.5%   
Avg. net profit/employee Rs Th1,480.61,369.1 108.1%   
INCOME DATA
Net Sales Rs m264,89519,685 1,345.7%  
Other income Rs m8,3881,143 733.9%   
Total revenues Rs m273,28220,828 1,312.1%   
Gross profit Rs m56,0815,003 1,121.0%  
Depreciation Rs m14,998663 2,263.9%   
Interest Rs m5,1764 123,231.0%   
Profit before tax Rs m44,2955,479 808.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-9,5050-   
Tax Rs m8,4521,878 450.0%   
Profit after tax Rs m26,3383,601 731.5%  
Gross profit margin %21.225.4 83.3%  
Effective tax rate %19.134.3 55.7%   
Net profit margin %9.918.3 54.4%  
BALANCE SHEET DATA
Current assets Rs m316,35924,167 1,309.0%   
Current liabilities Rs m198,6439,544 2,081.3%   
Net working cap to sales %44.474.3 59.8%  
Current ratio x1.62.5 62.9%  
Inventory Days Days9555 172.1%  
Debtors Days Days10829 375.2%  
Net fixed assets Rs m213,1789,514 2,240.8%   
Share capital Rs m2,399458 524.4%   
"Free" reserves Rs m378,60626,375 1,435.5%   
Net worth Rs m381,00626,832 1,420.0%   
Long term debt Rs m17,72125 70,883.6%   
Total assets Rs m643,02836,900 1,742.6%  
Interest coverage x9.61,305.5 0.7%   
Debt to equity ratio x00 4,991.9%  
Sales to assets ratio x0.40.5 77.2%   
Return on assets %4.99.8 50.2%  
Return on equity %6.913.4 51.5%  
Return on capital %10.020.4 49.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m40,81622 182,216.1%   
Fx outflow Rs m30,1431,489 2,024.8%   
Net fx Rs m10,673-1,466 -727.9%   
CASH FLOW
From Operations Rs m39,0723,318 1,177.6%  
From Investments Rs m-33,708-2,383 1,414.5%  
From Financial Activity Rs m-15,393-1,104 1,394.9%  
Net Cashflow Rs m-7,359-169 4,367.4%  

Share Holding

Indian Promoters % 63.7 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 5.1 7.5 68.4%  
FIIs % 23.0 4.9 469.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 23.7 35.0%  
Shareholders   133,026 85,207 156.1%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   PLETHICO PHARMA  BIOCON   FULFORD INDIA  ALKEM LABORATORIES  AJANTA PHARMA  

Compare SUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Get Ready for Record Highs(Podcast)

Globally, Traders were left scrambling after the Federal Reserve forecast zero interest-rate hikes this year and just one in 2020.

Related Views on News

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

PFIZER Announces Quarterly Results (3QFY19); Net Profit Up 51.2% (Quarterly Result Update)

Jan 25, 2019 | Updated on Jan 25, 2019

For the quarter ended December 2018, PFIZER has posted a net profit of Rs 1 bn (up 51.2% YoY). Sales on the other hand came in at Rs 5 bn (up 12.5% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER 2017-18 Annual Report Analysis (Annual Result Update)

Jan 1, 2019 | Updated on Jan 1, 2019

Here's an analysis of the annual report of PFIZER for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PFIZER. Also includes updates on the valuation of PFIZER.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

PFIZER Announces Quarterly Results (2QFY19); Net Profit Down 13.8% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, PFIZER has posted a net profit of Rs 958 m (down 13.8% YoY). Sales on the other hand came in at Rs 5 bn (down 9.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

More Views on News

Most Popular

My Top 3 Defence Stocks to Buy Now(The 5 Minute Wrapup)

Mar 19, 2019

The urgency to privatise India's defence sector to make India self-reliant was never as strong as it is today.

5 Fundamentally Strong Stocks to Pick for Trading Today(Profit Hunter)

Mar 15, 2019

5 fundamentally strong stocks one could buy to trade in this market right now. Make sure you grab the chance this strongly rallying market offers.

This Small Cap Stock Could Offer Triple Digit Gains from its Current Price(Profit Hunter)

Mar 19, 2019

If you are still waiting for signals, remember, there is no correct timing, only right time to Buy stocks. For select small caps, that time is now.

Elections Don't Matter!(The Honest Truth)

Mar 13, 2019

Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.

Two Growth Stocks that Doubled in a Little Over 12 Months!(The 5 Minute Wrapup)

Mar 13, 2019

The elements that fueled profit growth for these two companies led to a surge in their stock prices.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Mar 22, 2019 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS